Plain-English translation of NCT01890265 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Pulmonary fibrosis research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied , an experimental antibody designed to reduce lung scarring in patients with idiopathic pulmonary fibrosis (IPF). Participants received either the medication or a placebo as intravenous infusions every three weeks. The trial examined whether this treatment was safe and whether it could slow the progression of this serious lung disease.
Idiopathic pulmonary fibrosis is a progressive disease where lung tissue becomes increasingly scarred, making it harder to breathe over time. Current treatment options are limited, so researchers wanted to test whether this medication could help by targeting the scarring process itself.
Participants attended regular clinic visits to receive intravenous infusions of either the medication or placebo every three weeks for about 9 to 11 months, depending on which group they were in. A subset of patients also continued their existing IPF medications (pirfenidone or nintedanib) during the trial. Throughout the study, participants had blood tests and imaging scans to monitor their lung function and safety.
AI-generated summary from trial data · Oct 12, 2026 · Not medical advice
United States